Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDR NASDAQ:CORT NASDAQ:ESPR NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ACORTCorcept Therapeutics$71.95-2.7%$75.57$42.01▼$117.33$7.57B0.461.24 million shs881,710 shsESPREsperion Therapeutics$2.74+8.1%$2.40$0.69▼$3.94$549.42M0.965.34 million shs5.85 million shsLGNDLigand Pharmaceuticals$179.69+1.1%$163.72$93.58▼$186.40$3.52B0.95156,223 shs37,713 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics0.00%-16.10%+1.50%+1.64%+62.80%ESPREsperion Therapeutics0.00%-23.33%-10.92%+114.41%+28.43%LGNDLigand Pharmaceuticals0.00%-1.80%+7.23%+40.03%+72.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ACORTCorcept Therapeutics$71.95-2.7%$75.57$42.01▼$117.33$7.57B0.461.24 million shs881,710 shsESPREsperion Therapeutics$2.74+8.1%$2.40$0.69▼$3.94$549.42M0.965.34 million shs5.85 million shsLGNDLigand Pharmaceuticals$179.69+1.1%$163.72$93.58▼$186.40$3.52B0.95156,223 shs37,713 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics0.00%-16.10%+1.50%+1.64%+62.80%ESPREsperion Therapeutics0.00%-23.33%-10.92%+114.41%+28.43%LGNDLigand Pharmaceuticals0.00%-1.80%+7.23%+40.03%+72.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDRAlder Biopharmaceuticals 0.00N/AN/AN/ACORTCorcept Therapeutics 2.57Moderate Buy$135.2587.99% UpsideESPREsperion Therapeutics 2.50Moderate Buy$7.00155.94% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-1.78% DownsideCurrent Analyst Ratings BreakdownLatest ESPR, CORT, ALDR, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.0010/8/2025CORTCorcept TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/1/2025CORTCorcept TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/27/2025CORTCorcept TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/25/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$140.009/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.009/10/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$137.00 ➝ $140.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73CORTCorcept Therapeutics$716.08M10.59$1.21 per share59.55$6.49 per share11.09ESPREsperion Therapeutics$268.13M2.06$0.03 per share105.30($1.97) per share-1.39LGNDLigand Pharmaceuticals$167.13M21.07$1.62 per share110.61$43.95 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/ACORTCorcept Therapeutics$141.21M$1.1363.5438.89N/A18.51%20.10%16.20%10/29/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/A136.39-35.84%N/A-28.41%11/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A48.43N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest ESPR, CORT, ALDR, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A10/29/2025Q3 2025CORTCorcept Therapeutics$0.22N/AN/AN/A$223.78 millionN/A8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million7/31/2025Q2 2025CORTCorcept Therapeutics$0.23$0.29+$0.06$0.29$199.40 million$194.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDRAlder Biopharmaceuticals1.748.948.94CORTCorcept TherapeuticsN/A3.062.98ESPREsperion TherapeuticsN/A1.150.76LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDRAlder BiopharmaceuticalsN/ACORTCorcept Therapeutics93.61%ESPREsperion Therapeutics47.39%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALDRAlder Biopharmaceuticals15.40%CORTCorcept Therapeutics20.80%ESPREsperion Therapeutics1.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableCORTCorcept Therapeutics300105.37 million83.77 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableESPR, CORT, ALDR, and LGND HeadlinesRecent News About These CompaniesLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 13 at 2:23 AM | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 13 at 2:22 AM | marketbeat.comVillere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 11 at 5:46 AM | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss RatingsOctober 10 at 7:37 AM | marketbeat.comLigand partner SQ Innovation receives approval from FDA for Lasix ONYUOctober 9, 2025 | msn.comLigand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure PatientsOctober 9, 2025 | quiverquant.comQLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure PatientsOctober 9, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High - Here's What HappenedOctober 6, 2025 | marketbeat.comJohn Kozarich Sells 467 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockOctober 4, 2025 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 SharesOctober 3, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Purchased by Chicago Capital LLCSeptember 30, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?September 29, 2025 | marketbeat.comCongress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGNDSeptember 26, 2025 | marketbeat.comJason Aryeh Sells 10,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 25, 2025 | insidertrades.comArecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292September 25, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Director Sells $1,708,100.00 in StockSeptember 24, 2025 | marketbeat.comStrs Ohio Invests $789,000 in Ligand Pharmaceuticals Incorporated $LGNDSeptember 20, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High - Here's WhySeptember 19, 2025 | marketbeat.comContravisory Investment Management Inc. Takes Position in Ligand Pharmaceuticals Incorporated $LGNDSeptember 19, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by AnalystsSeptember 18, 2025 | marketbeat.comLigand Pharma Amends Credit Agreement for StabilitySeptember 16, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, CORT, ALDR, and LGND Company DescriptionsAlder Biopharmaceuticals NASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Corcept Therapeutics NASDAQ:CORT$71.94 -2.02 (-2.72%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Esperion Therapeutics NASDAQ:ESPR$2.74 +0.21 (+8.10%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Ligand Pharmaceuticals NASDAQ:LGND$179.69 +1.96 (+1.10%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
